4.57
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
What drives 4D Molecular Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
4D Molecular Therapeutics Inc. Stock Analysis and ForecastTremendous portfolio expansion - PrintWeekIndia
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionLong Term Secure Gain Stocks - Newser
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire
4DMT Reveals New Phase 2 Trial Results for Revolutionary Eye Disease Treatment at Major Conference - Stock Titan
What analysts say about 4D Molecular Therapeutics Inc. stockUnrivaled growth potential - Autocar Professional
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.56 Average Price Target from Analysts - Defense World
Is 4D Molecular Therapeutics Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Top Stocks for Aggressive Investors Top Growth StocksUnrivaled growth potential - Jammu Links News
Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech
4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration? - TipRanks
What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser
Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan
4D Molecular to layoff about 25% of workforce - MSN
Promising Penny Stocks To Consider In July 2025 - simplywall.st
4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital - MarketBeat
Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics Analyst Ratings: A Comprehensive Analysis - AInvest
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Nasdaq
East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals
4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener
4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire
4D Molecular to layoff about 25% of workforce (FDMT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener
Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com
Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World
Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):